Talis Biomedical Co. (NASDAQ:TLIS – Get Rating) was down 1% on Friday . The company traded as low as $0.59 and last traded at $0.60. Approximately 109,802 shares were traded during mid-day trading, a decline of 12% from the average daily volume of 124,413 shares. The stock had previously closed at $0.61.
Talis Biomedical Stock Performance
The company has a 50-day moving average of $0.54 and a 200-day moving average of $0.67.
Get
Talis Biomedical alerts:
Talis Biomedical (NASDAQ:TLIS – Get Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.24). Talis Biomedical had a negative return on equity of 59.90% and a negative net margin of 2,119.66%. The business had revenue of $0.80 million during the quarter, compared to the consensus estimate of $0.20 million. Research analysts predict that Talis Biomedical Co. will post -4.03 earnings per share for the current year.
Hedge Funds Weigh In On Talis Biomedical
A number of large investors have recently bought and sold shares of the business. Prelude Capital Management LLC raised its position in shares of Talis Biomedical by 36.2% during the 1st quarter. Prelude Capital Management LLC now owns 256,395 shares of the company's stock worth $362,000 after purchasing an additional 68,126 shares during the period. Millennium Management LLC bought a new position in Talis Biomedical during the 2nd quarter worth $164,000. Finally, Renaissance Technologies LLC increased its position in Talis Biomedical by 549.3% in the second quarter. Renaissance Technologies LLC now owns 107,765 shares of the company's stock worth $88,000 after buying an additional 91,167 shares during the period. Institutional investors own 47.08% of the company's stock.
Talis Biomedical Company Profile
(Get Rating)
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19.
Featured Stories
- Get a free copy of the StockNews.com research report on Talis Biomedical (TLIS)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
Receive News & Ratings for Talis Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talis Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
塔利斯生物医疗公司(TLIS-GET Rating)上周五下跌1%。该公司股价低至0.59美元，最新报0.60美元。午盘成交量约为109,802股，较124,413股的日均成交量下降12%。该股此前收盘价为0.61美元。
Talis Biomedical股票表现
该公司的50日移动均线切入位在0.54美元，200日移动均线切入位在0.67美元。
到达
塔利斯生物医学警报：
塔利斯生物医疗(纳斯达克：TLIS-GET Rating)最近一次公布季度收益是在11月3日星期四。该公司公布本季度每股收益(EPS)为0.98美元，低于分析师一致预期的0.74美元和0.24美元。Talis Biomedical的净资产回报率为负59.90%，净利润率为负2119.66%。该业务本季度的收入为80万美元，而普遍预期为20万美元。研究分析师预计，Talis Biomedical Co.本年度每股收益将达到4.03美元。
对冲基金入股Talis Biomedical
一些大型投资者最近买卖了该公司的股票。Prelude Capital Management LLC在第一季度将其在Talis Biomedical股票中的头寸提高了36.2%。Prelude Capital Management LLC现在拥有256,395股该公司的股票，价值362,000美元，在此期间又购买了68,126股。Millennium Management LLC在第二季度购买了Talis Biomedical的一个新头寸，价值16.4万美元。最后，复兴科技有限责任公司在第二季度将其在Talis Biomedical的头寸增加了549.3%。复兴科技有限责任公司现在拥有107,765股该公司的股票，价值88,000美元，在此期间又购买了91,167股。机构投资者持有该公司47.08%的股份。
Talis Biomedical公司简介
(获取评级)
Talis Biomedical Corporation是一家分子诊断公司。该公司正在开发Talis One系统，以解决现有传染病护理点诊断检测技术的局限性。它还为Talis One新冠肺炎提供检测系统，该系统专注于检测导致新冠肺炎的SARS-CoV-2病毒。
专题报道
- 免费获取StockNews.com关于Talis Biomedical(TLIS)的研究报告
- 市场回顾周-1/30-2/3
- 细价股值得吗？你应该投资细价股吗？
- Zimmer Biomet盈利节节攀升，增长可能被计入价格
- 人工智能软件制造商EPAM号称科技板块涨幅最大
- 福特股票在盈利大幅下滑后继续前进
接受《塔利斯生物医学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Talis Biomedical和相关公司的最新新闻和分析师评级的每日简要摘要。
